scholarly journals Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV‐1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine

2019 ◽  
Author(s):  
Nicole Bertoletti ◽  
Albert H. Chan ◽  
Raymond F. Schinazi ◽  
Y. Whitney Yin ◽  
Karen S. Anderson
Keyword(s):  
Reverse Transcriptase ◽  
Crystal Structures ◽  
Reverse Transcriptase Inhibitors ◽  
Nucleoside Reverse Transcriptase Inhibitors ◽  
Structural Insights ◽  
Hiv 1

scholarly journals An insight on promising strategies hoping to cure HIV-1 infection by targeting Rev protein—short review

2021 ◽  
Author(s):  
Sahana Pai ◽  
Jayesh Mudgal ◽  
B. Venkatesh Kamath ◽  
K. Sreedhara Ranganath Pai
Keyword(s):  
Reverse Transcriptase ◽  
Regulatory Protein ◽  
Short Review ◽  
Fixed Dose ◽  
Reverse Transcriptase Inhibitors ◽  
Nucleoside Reverse Transcriptase Inhibitors ◽  
Promising Therapeutic Target ◽  
Latent Hiv ◽  
Approved Drugs ◽  
Hiv 1

AbstractHuman immunodeficiency virus-1 (HIV-1) infection remains to be one of the major threats throughout the world. Many researchers are working in this area to find a cure for HIV-1. The group of the FDA approved drugs which are currently used against HIV-1 in the clinical practice include nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors (InIs), and protease inhibitors (PIs). Fixed dose combinations (FDCs) of these drugs are available and are used as per the anti-retroviral therapy (ART) guidelines. Despite these, unfortunately, there is no cure for HIV1 infection to date. The present review is focused upon describing the importance of a post-transcriptional regulatory protein “Rev”, responsible for latent HIV-1 infection as a possible, and promising therapeutic target against HIV-1.

Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy

2010 ◽  
Vol 18 (14) ◽  
pp. 5039-5047 ◽  
Author(s):  
Zhao-Sen Zeng ◽  
Qiu-Qin He ◽  
Yong-Hong Liang ◽  
Xiao-Qing Feng ◽  
Fen-Er Chen ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Reverse Transcriptase Inhibitors ◽  
Nucleoside Reverse Transcriptase Inhibitors ◽  
Anti Hiv ◽  
Hiv 1

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors

AIDS ◽  
2003 ◽  
Vol 17 (1) ◽  
pp. F1-F5 ◽  
Author(s):  
Bluma Brenner ◽  
Dan Turner ◽  
Maureen Oliveira ◽  
Daniela Moisi ◽  
Mervi Detorio ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Cross Resistance ◽  
Reverse Transcriptase Inhibitors ◽  
Nucleoside Reverse Transcriptase Inhibitors ◽  
Clade C ◽  
Hiv 1

Drivers of HIV-1 Drug Resistance to Non-Nucleoside Reverse-Transcriptase Inhibitors (NNRTIs) in Nine African Countries: A Modelling Study

2021 ◽  
Author(s):  
Julien Riou ◽  
Carole Dupont ◽  
Silvia Bertagnolio ◽  
Ravindra K. Gupta ◽  
Roger D. Kouyos ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Reverse Transcriptase ◽  
Reverse Transcriptase Inhibitors ◽  
African Countries ◽  
Nucleoside Reverse Transcriptase Inhibitors ◽  
Hiv 1 ◽  
Modelling Study

scholarly journals HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting

2019 ◽  
Vol 18 ◽  
pp. 232595821984906
Author(s):  
Nawaid Hussain Khan ◽  
Mikashmi Kohli ◽  
Kartik Gupta ◽  
Bimal Kumar Das ◽  
Ravindra Mohan Pandey ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Drug Resistant ◽  
Resistance Mutations ◽  
Reverse Transcriptase Inhibitors ◽  
Nucleoside Reverse Transcriptase Inhibitors ◽  
First Line Therapy ◽  
Resource Limited ◽  
High Prevalence ◽  
Hiv 1 ◽  
Limited Setting

Introduction: The present study aimed to report the prevalent HIV-1 drug-resistant mutations in patients with HIV-1 alone and tuberculosis (TB) coinfection alone to improve our understanding of the mutation patterns and aid treatment decisions. Methods: Patients with HIV-1 and HIV-TB on treatment for more than 1 year with suspected failure were recruited. Sequencing of protease and two-thirds of the region of reverse transcriptase gene was done for drug-resistant mutations. Results: In the HIV-TB group (n = 25), 88%, 92%, and 12% had mutations to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs), respectively. In the HIV-alone group (n = 25), 84%, 100%, and 4% had mutations to NRTIs, NNRTIs, and PIs, respectively. M184V, M41L, D67N, G190A, A98G, and K103N were the most common mutations seen. Conclusion: There is a high prevalence of drug-resistant mutations in HIV and HIV-TB coinfected patients.

Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains

2018 ◽  
Vol 26 (3) ◽  
pp. 661-674 ◽  
Author(s):  
Anna Maria Monforte ◽  
Laura De Luca ◽  
Maria Rosa Buemi ◽  
Fatima E. Agharbaoui ◽  
Christophe Pannecouque ◽  
...  
Keyword(s):  
Structural Optimization ◽  
Reverse Transcriptase ◽  
Wild Type ◽  
Reverse Transcriptase Inhibitors ◽  
Nucleoside Reverse Transcriptase Inhibitors ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document